Role of cytokine agonists and immune checkpoint inhibitors toward HIV remission.

ABSTRACT:

Purpose of review

The current article describes the current status of the use of cytokines and immune-checkpoint inhibitors as therapeutic strategies toward HIV remission.

Recent findings

Clinical trials using IL-2 and IL-7 showed increased levels of circulating T cells, although no reduction to the viral reservoir was observed. Studies in nonhuman primates (NHP) demonstrated that experimental IL-15 administration increased proliferation and cytotoxicity of simian immunodeficiency virus (SIV)-specific CD8 T cells, and promoted their localization to the lymph node (LN) B cell follicles. Immune checkpoint modulators targeting programed cell death-1 and cytotoxic T-lymphocyte associated protein 4, successfully used in oncologic diseases, have shown potential to restore HIV-spec

SUBMITTER: Hoang TN 

PROVIDER: S-EPMC6469389 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature